Schistosomiasis, also known as snail fever, is a disease caused by parasitic flatworms, called schistosomes.
The worms enter human skin that comes in contact with contaminated fresh water. They are found in sub-Saharan Africa, Middle East, Southeast Asia and the Caribbean.
Once in the bloodstream, the parasites usually first enter the urinary tract or the intestines. Initial symptoms include abdominal pain, bloody stools, diarrhea and blood in the urine. Long term infections can cause liver damage, kidney failure, infertility, bladder cancer and death.
The vaccine has shown to ameliorate disease, kills adult worms, and reduce fecundity in preclinical animal models, if proven clinically, could be a significant new tool added to the toolbox for global schistosomiasis elimination effort.
The Phase 1, open-label, dose-escalation trial will evaluate the safety and the immunogenicity of PAI Life Sciences's SchistoShield vaccine candidate in 45 healthy adults between 18 and 55 years of age.
Five treatment groups, each including nine subjects, will receive three intramuscular injections at different doses.
One group will receive the vaccine without an adjuvant (which acts to increase immune responses) and four will receive the vaccine with an adjuvant. Estimated completion date is April 2024.
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health is sponsoring the Phase 1 trial.
The study site is Kaiser Permanente Washington Health Research Institute, one of the NIAID- funded Vaccine and Treatment Evaluation Units; Lisa Jackson, MD, MPH, senior investigator, is the study principal investigator.
PAI Life Sciences Inc. licensed the vaccine from the Texas Tech University Health Sciences Center.
Texas Tech University Health Sciences Center (TTUHSC) is a comprehensive institution of higher education that also provides patient care and conducts biomedical clinical research across six campuses in the state of Texas.
The university, which is comprised of six schools (medicine, nursing, health professions, pharmacy, graduate school of biomedical sciences and population and public health), graduates more health care professionals than any other institution in the state.
The institution achieved Carnegie Classification status for Special Focus Four-Year Research Institutions in 2022 and is a recognized Hispanic Serving Institution by the US Department of Education.
Founded in 1969, TTUHSC has trained more than 28,000 health care professionals to date and is a member of the Texas Tech University System.
PAI Life Sciences is a biotechnology company located in Seattle, Washington, specialized in the developmental and translational research necessary to bring products from the laboratory to bedside.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial